Patent ID: 11925675
Assignee: SAREPTA THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating muscular dystrophy in a subject in need thereof, comprising the step of administering a recombinant adeno-associated virus (rAAV) scAAVrh74.MHCK7.hSGCG to the subject, wherein the rAAV is administered using a systemic route of administration and at a dose of about 4.63×1012 vg/kg, about 1.85×1013 vg/kg, or about 7.41×1013 vg/kg based on a linearized plasmid as the quantitation standard, and wherein the rAAV comprises a nucleotide sequence that is identical to SEQ ID NO: 7 or SEQ ID NO: 10.